Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

  • Read more about Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

The RAPID COVID-19 TRIAGE Algorithm

  • Read more about The RAPID COVID-19 TRIAGE Algorithm

COVID19-hematological Malignancies: the Italian Hematology Alliance

  • Read more about COVID19-hematological Malignancies: the Italian Hematology Alliance

Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease

  • Read more about Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease

Acute Kidney Injury and Acute Kidney Disease in COVID-19

  • Read more about Acute Kidney Injury and Acute Kidney Disease in COVID-19

French Single Centre Experience of Critically Ill Patients With Covid 19

  • Read more about French Single Centre Experience of Critically Ill Patients With Covid 19

COVID-19 and Cancer Consortium Registry

  • Read more about COVID-19 and Cancer Consortium Registry

Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

  • Read more about Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19

  • Read more about Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19

RemeGen, Ltd.

By efain on Wed, 04/22/2020 - 14:19
  • Read more about RemeGen, Ltd.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 218
  • Page 219
  • Page 220
  • Page 221
  • Current page 222
  • Page 223
  • Page 224
  • Page 225
  • Page 226
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA